Background: Applications in clinical medicine can benefit from fusion of spectroscopy data with anatomical imagery. For example, new 3-dimensional (3D) spectroscopy techniques allow for improved correlation of metabolite profiles with specific regions of interest in anatomical tumor images, which can be useful in characterizing and treating heterogeneous tumors that appear structurally homogeneous. Objectives: We sought to develop a clinical workflow and uniquely capable custom software tool to integrate advanced 3-tesla 3D proton magnetic resonance spectroscopic imaging (1H-MRSI) into industry standard image-guided neuronavigation systems, especially for use in brain tumor surgery. Methods:1H-MRSI spectra from preoperative scanning on 15 patients with recurrent or newly diagnosed meningiomas were processed and analyzed, and specific voxels were selected based on their chemical contents. 3D neuronavigation overlays were then generated and applied to anatomical image data in the operating room. The proposed 3D methods fully account for scanner calibration and comprise tools that we have now made publicly available. Results: The new methods were quantitatively validated through a phantom study and applied successfully to mitigate biopsy uncertainty in a clinical study of meningiomas. Conclusions: The proposed methods improve upon the current state of the art in neuronavigation through the use of detailed 3D 1H-MRSI data. Specifically, 3D MRSI-based overlays provide comprehensive, quantitative visual cues and location information during neurosurgery, enabling a progressive new form of online spectroscopy-guided neuronavigation.

Keywords:
Biopsy, Image-guided surgery, Magnetic resonance spectroscopy, Meningioma neuronavigation
1.
McKnight TR, von dem Bussche MH, Vigneron DB, Lu Y, Berger MS, McDermott MW, Dillon WP, Graves EE, Pirzkall A, Nelson SJ: Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence. J Neurosurg 2002;97:794-802.
2.
Kanberoglu B, Debbins J, Karam L: Accurate brain tumor biopsy using 1H-MRS neuronavigation. Proc Int Soc Mag Reson Med Meet, Stockholm, 2010, p 944.
3.
Pfisterer WK, Hendricks WP, Scheck AC, Nieman RA, Birkner TH, Krampla WW, Preul MC: Fluorescent in situ hybridization and ex vivo 1H magnetic resonance spectroscopic examinations of meningioma tumor tissue: is it possible to identify a clinically aggressive subset of benign meningiomas? Neurosurgery 2007;61:1048-1059.
4.
Pfisterer WK, Nieman RA, Scheck AC, Coons SW, Spetzler RF, Preul MC: Using ex vivo proton magnetic resonance spectroscopy to reveal associations between biochemical and biological features of meningiomas. Neurosurg Focus 2010;28:E12.
5.
Majos C, Alonso J, Aguilera C, Serrallonga M, Perez-Martin J, Acebes JJ, Arus C, Gili J: Proton magnetic resonance spectroscopy (1H MRS) of human brain tumours: assessment of differences between tumour types and its applicability in brain tumour categorization. Eur Radiol 2003;13:582-591.
6.
Preul MC, Caramanos Z, Collins DL, Villemure JG, Leblanc R, Olivier A, Pokrupa R, Arnold DL: Accurate, noninvasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy. Nat Med 1996;2:323-325.
7.
Preul MC, Caramanos Z, Leblanc R, Villemure JG, Arnold DL: Using pattern analysis of in vivo proton MRSI data to improve the diagnosis and surgical management of patients with brain tumors. NMR Biomed 1998;11:192-200.
8.
Sibtain NA, Howe FA, Saunders DE: The clinical value of proton magnetic resonance spectroscopy in adult brain tumours. Clin Radiol 2007;62:109-119.
9.
Stadlbauer A, Moser E, Gruber S, Nimsky C, Fahlbusch R, Ganslandt O: Integration of biochemical images of a tumor into frameless stereotaxy achieved using a magnetic resonance imaging/magnetic resonance spectroscopy hybrid data set. J Neurosurg 2004;101:287-294.
10.
Chernov MF, Muragaki Y, Ochiai T, Taira T, Ono Y, Usukura M, Maruyama T, Nakaya K, Nakamura R, Iseki H, Kubo O, Hori T, Takakura K: Spectroscopy-supported frame-based image-guided stereotactic biopsy of parenchymal brain lesions: comparative evaluation of diagnostic yield and diagnostic accuracy. Clin Neurol Neurosurg 2009;111:527-535.
11.
Stadlbauer A, Moser E, Gruber S, Buslei R, Nimsky C, Fahlbusch R, Ganslandt O: Improved delineation of brain tumors: an automated method for segmentation based on pathologic changes of 1H-MRSI metabolites in gliomas. Neuroimage 2004;23:454-461.
12.
Hermann EJ, Hattingen E, Krauss JK, Marquardt G, Pilatus U, Franz K, Setzer M, Gasser T, Tews DS, Zanella FE, Seifert V, Lanfermann H: Stereotactic biopsy in gliomas guided by 3-tesla 1H-chemical-shift imaging of choline. Stereotact Funct Neurosurg 2008;86:300-307.
13.
Ng WH, Lim T: Targeting regions with highest lipid content on MR spectroscopy may improve diagnostic yield in stereotactic biopsy. J Clin Neurosci 2008;15:502-506.
14.
Son BC, Kim MC, Choi BG, Kim EN, Baik HM, Choe BY, Naruse S, Kang JK: Proton magnetic resonance chemical shift imaging (1H CSI)-directed stereotactic biopsy. Acta Neurochir (Wien) 2001;143:45-49.
15.
Ganslandt O, Stadlbauer A, Fahlbusch R, Kamada K, Buslei R, Blumcke I, Moser E, Nimsky C: Proton magnetic resonance spectroscopic imaging integrated into image-guided surgery: correlation to standard magnetic resonance imaging and tumor cell density. Neurosurgery 2005;56:291-298.
16.
Frati A, Pichierri A, Bastianello S, Raco A, Santoro A, Esposito V, Giangaspero F, Salvati M: Frameless stereotactic cerebral biopsy: our experience in 296 cases. Stereotact Funct Neurosurg 2011;89:234-245.
17.
Chernov M, Muragaki Y, Taira T, Iseki H: 1H-MRS-guided stereotactic brain biopsy. Stereotact Funct Neurosurg 2012;90:63-65.
18.
Moore NZ: Meningiomas Associated with in vivo 3D 1H-Magnetic Resonance Spectroscopy Integrated into a Standard Image Guided Neurosurgical System: Determining Biochemical Markers of Clinically Aggressive Behavior and Providing a Resection Advantage; thesis, University of Arizona College of Medicine, 2012.
19.
Kanberoglu B, Karam L, Trouard T, Debbins J: Scanner calibration for multisite geometric accuracy: how to do it. Proc Int Soc Mag Reson Med Meet, Honolulu, 2009, p 4638.
20.
Jack CR Jr, Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, Borowski B, Britson PJ, Whitwell L, Ward C, Dale AM, Felmlee JP, Gunter JL, Hill DL, Killiany R, Schuff N, Fox-Bosetti S, Lin C, Studholme C, DeCarli CS, Krueger G, Ward HA, Metzger GJ, Scott KT, Mallozzi R, Blezek D, Levy J, Debbins JP, Fleisher AS, Albert M, Green R, Bartzokis G, Glover G, Mugler J, Weiner MW: The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging 2008;27:685-691.
21.
Jovicich J, Czanner S, Greve D, Haley E, van der Kouwe A, Gollub R, Kennedy D, Schmitt F, Brown G, Macfall J, Fischl B, Dale A: Reliability in multi-site structural MRI studies: effects of gradient non-linearity correction on phantom and human data. Neuroimage 2006;30:436-443.
22.
Jovicich J, Czanner S: Gradient non-linearity distortion correction software. http://www.birncommunity.org/tools-catalog/gradient-non-linearity-distortion-correction.
23.
Sled JG, Zijdenbos AP, Evans AC: A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging 1998;17:87-97.
24.
Sled JG: Non-parametric non-uniform intensity normalization software. http://www.nitrc.org/projects/nu_correct.
25.
Landau S: Aqual2 (A-cceptance QUAL-ification tool) software. http://loni.usc.edu/Software/Aqual2.
26.
Zitova B, Flusser J: Image registration methods: a survey. Image Vis Comput 2003;21:977-1000.
27.
Provencher SW: Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993;30:672-679.
28.
Keys RG: Cubic convolution interpolation for digital image processing. IEEE Trans Acoust Speech Signal Process 1981;29:1153-1160.
29.
McLean MA, Woermann FG, Barker GJ, Duncan JS: Quantitative analysis of short echo time 1H-MRSI of cerebral gray and white matter. Magn Reson Med 2000;44:401-411.
30.
Ala-Korpela M, Posio P, Mattila S, Korhonen A, Williams SR: Absolute quantification of phospholipid metabolites in brain-tissue extracts by 1H NMR spectroscopy. J Magn Reson B 1996;113:184-189.
31.
Govindaraju V, Young K, Maudsley AA: Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed 2000;13:129-153.
32.
Lehnhardt FG, Rohn G, Ernestus RI, Grune M, Hoehn M: 1H- and 31P-MR spectroscopy of primary and recurrent human brain tumors in vitro: malignancy-characteristic profiles of water soluble and lipophilic spectral components. NMR Biomed 2001;14:307-317.
33.
Monleon D, Morales JM, Gonzalez-Darder J, Talamantes F, Cortes O, Gil-Benso R, Lopez-Gines C, Cerda-Nicolas M, Celda B: Benign and atypical meningioma metabolic signatures by high-resolution magic-angle spinning molecular profiling. J Proteome Res 2008;7:2882-2888.
34.
Ratai EM, Pilkenton S, Lentz MR, Greco JB, Fuller RA, Kim JP, He J, Cheng LL, Gonzalez RG: Comparisons of brain metabolites observed by HRMAS 1H NMR of intact tissue and solution 1H NMR of tissue extracts in SIV-infected macaques. NMR Biomed 2005;18:242-251.
35.
Xu M, Ye J, Yang D, Xu X, Yeo TT, Ng WH, Lim CC: Ex-vivo NMR of unprocessed tissue in water: a simplified procedure for studying intracranial neoplasms. Anal Bioanal Chem 2007;389:2153-2159.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.